Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

NCT01894165 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Molybdenum Cofactor Deficiency (MoCD)
Rare Autosomal Recessive Disorder
Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

Interventions

DRUG: ALXN1101
DRUG: Placebo

Sponsor

Origin Biosciences